Please login to the form below

Not currently logged in
Email:
Password:

Rigel

This page shows the latest Rigel news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs. Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Rigel is also developing it for additional indications, including autoimmune haemolytic anaemia and IgA

Latest news

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Rigel shaken after fostamatinib misses phase III trial target. Firm will still pursue early 2017 FDA approval for the autoimmune disease therapy. ... In August, Rigel reported the same 18% response rate for fostamatinib in the FIT 1 trial.

  • BMS buys immunotherapy specialist Flexus in $1.2bn deal BMS buys immunotherapy specialist Flexus in $1.2bn deal

    BMS buys immunotherapy specialist Flexus in $1.2bn deal. And signs new cancer research partnership with Rigel. ... Meanwhile, this announcement was made on the same day that BMS also made public a new immuno-oncology partnership with Rigel.

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    Rigel plans job cuts in R&D restructure. Follows failure of fostamatinib disodium in rheumatoid arthritis trial. ... Rigel said it expects to advance one of these two molecules into a phase 3 clinical programme by 2015.

  • Rigel on the slide as asthma drug falls over Rigel on the slide as asthma drug falls over

    Rigel on the slide as asthma drug falls over. Share plummet after phase II failure of R343. ... Shares in US pharma company Rigel took a nosedive yesterday after an asthma drug in development at the company failed a phase II trial.

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    Other respiratory prospects for AZ include the JAK inhibitor R256 licensed last year from Rigel Pharmaceuticals in a deal that could be worth up to $100m.

More from news
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Pharma deals in February 2015 Pharma deals in February 2015

    February saw BMS further signal its intention to lead in this space announcing two simultaneous deals, the acquisition of Flexus Biosciences and a collaboration with Rigel. ... The earlier stage collaborative deal with Rigel is to develop and

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors - immuno-oncology.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics